![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Xillix develops, manufactures and markets technologies that captures and process images used in the early detection of cancer. Overview: The company has received preliminary approval from the U.S. Food and Drug Administration of the company's cancer detection devices and made international marketing alliances, making it the hottest small-ap biotech story of the year. Internet:http://www.xillix.com Business Highlights:* Received U.S. FDA approval for its auto-florescence bronchoscope to inspect lungs for cancerous tissue for early lung cancer detection. It has already achieved European regulatory approval. *the company is expanding its marketing pact with Tokyo-based Olympus Optical for granting worldwide distribution and marketing rights to Olympus for its Life-Lung imaging technology. *AccuMed international said it signed a letter of intent to acquire a one-third stake in Xillix's Oncometrics unite. *The unite has several poducts to launch including a device for automating the Pap smear test for cervical cancer. (SYMBOL-XLX on TSE $4.20 Canadian) | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |